Precision Radiotherapy Enabled by Molecular MRI

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologic confirmation of glioblastoma or grade 4 astrocytoma

• Age \>18

• KPS at least 60

• Patients must have normal organ and marrow function as defined below:

‣ leukocytes \>3,000/mcL

⁃ absolute neutrophil count \>1,500/mcL

⁃ platelets \>100,000/mcL

⁃ total bilirubin within normal institutional limits

⁃ AST(SGOT)/ALT(SGPT) \<2.5

⁃ institutional upper limit of normal

⁃ creatinine within normal institutional limits OR creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

• Patients of child-bearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child.

• Ability to understand and the willingness to sign a written informed consent document.

Locations
United States
Maryland
Johns Hopkins University
RECRUITING
Baltimore
Contact Information
Primary
Kristin Redmond
kjanson3@jhmi.edu
410-614-1642
Backup
Ryan Manuel
rmanuel5@jhmi.edu
410-955-4261
Time Frame
Start Date: 2026-04-29
Estimated Completion Date: 2032-05
Participants
Target number of participants: 20
Treatments
Experimental: Amide proton transfer radiotherapy (APT-RT)
Amide proton transfer radiotherapy (APT-RT) is weighted imaging that may enhance visualization of tumor infiltration and could reduce the risk of radiation toxicity while still effectively irradiating the tumor.
Active_comparator: Standard radiotherapy (RT)
Related Therapeutic Areas
Sponsors
Collaborators: The Ben & Catherine Ivy Foundation
Leads: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

This content was sourced from clinicaltrials.gov